HLA class II susceptibility to cervical cancer among Tunisian women

Bulletin du Cancer

Volumn 99, Issue 9, 2012, Pages

  Ben Othmane, Yosra ^a   Ghazouani, Ezzeddine ^b   Mezlini, Amel ^c   Lagha, Awatef ^b   Raïs, Mejda ^b   Kochkar, Radhia ^b   Zidi, Sabrina ^a   Afrit, Mehdi ^c   Mota Vieira, Luisa ^d,e   Yacoubi Loueslati, Besma ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b MILITARY HOSPITAL OF TUNIS   (Tunisia)

^c Salah Azeiz Oncology Institute   (Tunisia)

^d EPE   (Tunisia)

^e INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Cervical cancer; HLA DQB1; HLA DRB1

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HLA ANTIGEN CLASS 2 DQB1 GENE; HLA ANTIGEN CLASS 2 DRB1 GENE; HUMAN; HUMAN TISSUE; INVASIVE CERVICAL CANCER; MAJOR CLINICAL STUDY; SQUAMOUS CELL CARCINOMA; TUNISIA; UTERINE CERVIX CANCER; ADENOCARCINOMA; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; MIDDLE AGED; PATHOLOGY; SARCOMA; UTERINE CERVIX TUMOR;

HLA DQ ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HLA-DQB1 ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; SARCOMA; TUNISIA; UTERINE CERVICAL NEOPLASMS;

EID: 84867113570     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1623     Document Type: Article

References (32)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97 : 72-81.
2. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286 : 3106-14. (Pubitemid 34016525)
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 : 518-27. (Pubitemid 36159887)
4. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55 : 244-65. (Pubitemid 34293391)
5. Mota F, Rayment N, Chong S, et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999; 116 : 33-40. (Pubitemid 29170001)
6. Piersma SJ, Welters MJ, van der Hulst JM, et al. Human papillomavirus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008; 122 : 486-94. (Pubitemid 350308938)
7. Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol 2002; 21 : 153-72. (Pubitemid 34791938)
8. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002; 2 : 277-88. (Pubitemid 37328781)
9. Hildesheim A,Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89 : 229-40. (Pubitemid 35351541)
10. Zoodsma M, Nolte IM, Schipper M, et al. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet 2005; 42 : 1-6.
11. Helland A, Borresen AL, Kaern J, et al. HLA antigens and cervical carcinoma. Nature 1992; 356 : 22-3.
12. Sanjeev CB, Hjelmstrom P, Hallman P, et al. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type 16 seropositive and seronegative Swedish women. Int J Cancer 1996; 68 : 409-14. (Pubitemid 26414491)
13. Cuzick J, Terry G, Ho L, et al. Association between highrisk HPV types, HLA DRB1*and DQB1*alleles and cervical cancer in British women. Br J Cancer 2000; 82 : 1348-52. (Pubitemid 30145357)
14. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001; 93 : 817-22. (Pubitemid 32756751)
15. Wang SS, Wheeler CM, Hildesheim A, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001; 184 : 1310-4. (Pubitemid 33055576)
16. Schneider S, Roessli D, Excoffier L. Arlequin: software for population genetics data analysis. Place: 2.0 Edn Genetics and Biometry Laboratory. Geneva, Switzerland : Department of Anthropology, University of Geneva, 2000.
17. Wu Y, Zhang Q, Liu B, Yu G. The analysis of the entire HLA, partial non-HLA and HPV for Chinese women with cervical cancer. J Med Virol 2008; 80 : 1808-13.
18. Bhattacharya P, Sengupta S. Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens 2007; 70 : 283-93. (Pubitemid 47340723)
19. Apple RJ, Erlich HA, Klitz W, et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994; 6 : 157-62. (Pubitemid 24188596)
20. Krul EJT, Schippe RF, Schreuder GMT, et al. HLA and susceptibility to cervical neoplasia. Hum Immunol 2000; 60 : 337-42. (Pubitemid 29239568)
21. Helland A, Olsen AO, Gjøen K, et al. An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women. Int J Cancer 1998; 76 : 19-24. (Pubitemid 28164563)
22. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001; 93 : 817-22. (Pubitemid 32756751)
23. Kohaara I, Hussainb S, Thakur N, et al. Association between human leukocyte antigen class II alleles and human papillomavirus-mediated cervical cancer in Indian women. Hum Immunol 2009; 70 : 222-9.
24. Maciag PC, Schlecht NF, Souza PS, et al. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000; 9 : 1183-91.
25. Odunsi K, Terry G, Ho L, et al. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996; 67 : 595-602. (Pubitemid 26300972)
26. Brady CS, Duggan-Keen MF, Davidson JA, et al. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol 1999; 80 : 3233-40.
27. Lin P, Koutsky LA, Critchlow CW, et al. HLA class II DR-DQ and increased risk of cervical cancer among Senegalese women. Cancer Epidemiol Biomarkers Prev 2001; 10 : 1037-45. (Pubitemid 32959150)
28. Hildesheim A, Schiffman M, Scott DR, et al. HLA class I/II alleles and development of HPV-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7 : 1035-41. (Pubitemid 28514105)
29. Beskow AH, Gyllensten UB. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 2002; 101 : 526-31.
30. Ades S, Koushik A, Duarte-Franco E, et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008; 122 : 2820-6. (Pubitemid 351649329)
31. Beskow AH, Moberg M, Gyllensten UB. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int J Cancer 2005; 117 : 510-4. (Pubitemid 41429577)
32. MalhotraU, Holte S, Dutta S, et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001; 107 : 505-17. (Pubitemid 32167997)